ArticleCancer cell2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05440864 (Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma), which is not on this map. Cited by 400 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
400citing papers in PubMed, 4 pooled it
27.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)
Who cites it
400 citing papers in PubMed, 4 syntheses or guidelines pooled it, 568 citations in OpenAlex.
- Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis.Targeted oncology · 2026Pooled it
- Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.Molecules (Basel, Switzerland) · 2022Pooled it
- Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.Cancer medicine · 2022Pooled it
- In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Frontiers in immunology · 2022Pooled it
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Cell reports. Medicine · 2026Trial
- Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.Cancer discovery · 2025Trial
- Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nature medicine · 2024Trial
- Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.Journal for immunotherapy of cancer · 2024Trial
- Trial
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity.Cancer research · 2026Article
- Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non-Small Cell Lung Cancer: Mechanisms to Clinical Translation.Cancer medicine · 2026Review
- Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.Nature cancer · 2026Article
- Fc-engineering for improved cancer immunotherapy.Biochemical Society transactions · 2026Review
- Human Antibody Isotypes, Subclasses, Allotypes and Fc Biology: Clinical Implications in Infectious Diseases, Autoimmunity, and Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Improving Anti-CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.Journal of experimental & clinical cancer research : CR · 2026Article
- Lymph node fine-tuning FcγR signaling boosts anti-PD-1 therapy.Journal for immunotherapy of cancer · 2026Article
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
340 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors at 7 institutions in 2 countries.
Frederick Arce VargasCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Andrew J S FurnessCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK; The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Kevin LitchfieldTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Kroopa JoshiCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK; The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Rachel RosenthalBill Lyons Informatics Centre, UCL Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6DD, UK.
Ehsan GhoraniCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Isabelle SolomonCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Marta H LeskoCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Nora RuefCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Claire RoddieCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Jake Y HenryCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Lavinia SpainThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Assma Ben AissaCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Andrew GeorgiouCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Yien Ning Sophia WongCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Myles SmithThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Dirk StraussThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Andrew HayesThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
David NicolThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Tim O'BrienGuy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK.
Linda MårtenssonBioInvent International AB, 223 70 Lund, Sweden.
Anne LjungarsBioInvent International AB, 223 70 Lund, Sweden.
Ingrid TeigeBioInvent International AB, 223 70 Lund, Sweden.
Björn FrendéusBioInvent International AB, 223 70 Lund, Sweden.
TRACERx Melanoma
TRACERx Renal
TRACERx Lung consortia
Martin PuleResearch Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK.
Teresa MarafiotiDepartment of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
Martin GoreThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
James LarkinThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Samra TurajlicThe Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Charles SwantonTranslational Cancer Therapeutics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6DD, UK; Translational Cancer Therapeutics Laboratory, UCL Cancer Institute, London WC1E 6DD, UK.
Karl S PeggsCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK. Electronic address: k.peggs@ucl.ac.uk.
Sergio A QuezadaCancer Immunology Unit, University College London (UCL) Cancer Institute, London WC1E 6DD, UK; Research Department of Haematology, UCL Cancer Institute, London WC1E 6DD, UK. Electronic address: s.quezada@ucl.ac.uk.
CRUK Lung Cancer Centre of Excellence · GBRoyal Marsden NHS Foundation Trust · GBBioInvent (Sweden) · SECancer Research UK · GBThe Francis Crick Institute · GBUniversity College Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GB
Funding
Cancer Research UK 16463Cancer Research UK 17786Cancer Research UK 18176Cancer Research UK 19278Cancer Research UK 20265Cancer Research UK 20276Cancer Research UK 20764Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK C11496/A17786Cancer Research UK C33499/A20265Cancer Research UK C36463/A20764Cancer Research UK C36463/A22246Cancer Research UK C416/A18088Cancer Research UK C5759/A20465Department of HealthMedical Research Council MC_UP_1203/1Medical Research Council MR/P014712/1
Abstract
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the CD8
Indexed as
Polymorphism, Single NucleotideAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCell Line, TumorCTLA-4 AntigenFemaleHumansIpilimumabMelanomaMiceReceptors, IgGT-Lymphocytes, RegulatoryTreatment OutcomeXenograft Model Antitumor AssaysAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCTLA-4 AntigenCTLA4 protein, humanFCGR3A protein, humanIpilimumabReceptors, IgGtremelimumabantibody-dependent cell-mediated cytotoxicityCTLA-4Fc-gamma receptorsIgG subclassimmune checkpointsimmune regulatory antibodiesipilimumabregulatory T cell depletiontremelimumabtumor immunotherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05440864ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.